SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DISCLOSURES
respective mutations/target expressions may “build a bridge” until more refined, immune cell
activating regimens become available. Always looking for suitable clinical studies needs to
complement this evaluation.
References:
1. Gandhi UH, Cornell RF, Lakshman A, et al. POutcomes of patients with multiple myeloma
refractory to CD38-targeted monoclonal antibody therapy Leukemia. 2019; Leukemia.
2019; 33: 2266-2275
2. Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell
leukemia; current status and future directions. Blood Cancer J. 2021 ; 11: 23
3. Rasche L, Strifler S, Duell J, et al. The lymphoma-like polychemotherapy regimen "Dexa-
BEAM" in advanced and extramedullary multiple myeloma. Ann Hematol. 2014; 93: 1207-
1214
4. Laganà A, Beno I, Melnekoff D, et al. Precision Medicine for Relapsed Multiple Myeloma on
the Basis of an Integrative Multiomics Approach. JCO Precis Oncol. 2018;2018:PO.18.00019.
5. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory
Multiple Myeloma. N Engl J Med. 2021; 384: 705-771